Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine

Vaccine

Volumn 25, Issue 6, 2007, Pages 1076-1084

  Imoto, Jun ichi ^a   Konishi, Eiji ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Combined immunization; Dengue tetravalent DNA vaccine; Needle free injection

Indexed keywords

DENGUE VACCINE; DNA VACCINE; ENVELOPE PROTEIN; JAPANESE ENCEPHALITIS VACCINE; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIREMIA; VIRUS STRAIN;

ANIMALS; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; JAPANESE ENCEPHALITIS VACCINES; MALE; MICE; MICE, INBRED BALB C; VACCINES, COMBINED; VACCINES, DNA; VACCINES, INACTIVATED; VERO CELLS; VIREMIA;

EID: 33845598030     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.09.059     Document Type: Article

References (37)

1. Burke D.S., and Monath T.P. Flavivirus. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 4th ed. (2001), Lippincott Williams & Willkins, Philadelphia 1043-1125
2. Kurane I., and Takasaki T. Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large. Rev Med Virol 11 (2001) 301-311
3. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 (2002) 100-103
4. Halstead S.B., and Deen J. The future of dengue vaccines. Lancet 360 (2002) 1243-1245
5. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 83 (2005) 308-314
6. Hombach J., Barrett A.D., Cardosa M.J., Deubel V., Guzman M., Kurane I., et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health. 26-27 April 2004, Bangkok, Thailand. Vaccine 23 (2005) 2689-2695
7. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66 (2002) 264-272
8. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23 (2004) 99-109
9. Innis B.L., and Eckels K.H. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 69 (2003) 1-4
10. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (2003) 48-60
11. Simmons M., Murphy G.S., and Hayes C.G. Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65 (2001) 159-161
12. Markoff L., Pang X., Houng Hs H.S., Falgout B., Olsen R., Jones E., et al. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 76 (2002) 3318-3328
13. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., and Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77 (2003) 11436-11447
14. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78 (2004) 4761-4775
15. Blaney Jr. J.E., Matro J.M., Murphy B.R., and Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79 (2005) 5516-5528
16. Raviprakash K., Apt D., Brinkman A., Skinner C., Yang S., Dawes G., et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 353 (2006) 166-173
17. Robinson H.L., and Pertmer T.M. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 55 (2000) 1-74
18. Putnak R., Porter K., and Schmaljohn C. DNA vaccines for flaviviruses. Adv Virus Res 61 (2003) 445-468
19. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 (2005) 633-639
20. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
21. Konishi E., Kosugi S., and Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24 (2006) 2200-2207
22. Lindenbach B.D., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 4th ed. (2001), Lippincott Williams & Willkins, Philadelphia 991-1041
23. Konishi E., and Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20 (2002) 1058-1067
24. Wolff J.A., and Budker V. The mechanism of naked DNA uptake and expression. Review. Adv Genet 54 (2005) 3-20
25. Alpar H.O., Papanicolaou I., and Bramwell V.W. Strategies for DNA vaccine delivery. Review. Expert Opin Drug Deliv 2 (2005) 829-842
26. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 4 (2002) 23-27
27. Moore A.C., and Hill A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199 (2004) 126-143
28. Konishi E., Terazawa A., and Imoto J. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Vaccine 21 (2003) 1826-1832
29. Konishi E., Terazawa A., and Fujii A. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine 21 (2003) 3713-3720
30. Imoto J., and Konishi E. Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. Viral Immunol 18 (2005) 205-212
31. Konishi E., Yamaoka M., Kurane I., and Mason P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18 (2000) 1133-1139
32. Konishi E., Yamaoka M., Khin-Sane-Win, Kurane I., and Mason P.W. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding JE virus premembrane and envelope genes. J Virol 72 (1998) 4925-4930
33. Biswas S., Reddy G.S., Srinivasan V.A., and Rangarajan P.N. Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum Gene Ther 12 (2001) 1917-1922
34. Giacalone M.J., Sabbadini R.A., Chambers A.L., Pillai S., and McGuire K.L. Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery. Vaccine 24 (2006) 6009-6017
35. Hommel D., Talarmin A., Deubel V., Reynes J.M., Drouet M.T., Sarthou J.L., et al. Dengue encephalitis in French Guiana. Res Virol 149 (1998) 235-238
36. Association for Laboratory Animal Science, editor. Advanced Laboratory Animal Science and Technology. Tokyo, Japan: Adthree; 2004 [in Japanese].
37. Konishi E., Ajiro N., Nukuzuma C., Mason P.W., and Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 21 (2003) 3675-3683